|
Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen
FierceBiotech Genentech, though, appears to be out front with its new antibody–which Amgen had dubbed AMG 282–now headed into Phase II for asthma and COPD as investigators set out to see if they can control the diseases by shutting down the IL-33 pathway. |
View full post on asthma – Google News